Thymoquinone-loaded nanostructured lipid carriers: preparation, gastroprotection, in vitro toxicity, and pharmacokinetic properties after extravascular administration

Background Nanostructured lipid carriers (NLCs), composed of solid and liquid lipids, and surfactants are potentially good colloidal drug carriers. Thymoquinone is the main bioactive compound of Nigella sativa. In this study, the preparation, gastroprotective effects, and pharmacokinetic (PK) properties of thymoquinone (TQ)-loaded NLCs (TQNLCs) were evaluated. Method TQNLCs were prepared using hydrogenated palm oil (Softisan® 154), olive oil, and phosphatidylcholine for the lipid phase and sorbitol, polysorbate 80, thimerosal, and double distilled water for the liquid lipid material. A morphological assessment of TQNLCs was performed using various methods. Analysis of the ulcer index, hydrogen concentration, mucus content, and biochemical and histochemical studies confirmed that the loading of TQ into the NLCs significantly improved the gastroprotective activity of this natural compound against the formation of ethanol-induced ulcers. The safety of TQNLC was tested on WRL68 liver normal cells with cisplatin as a positive control. Results The average diameter of the TQNLCs was 75 ± 2.4 nm. The particles had negative zeta potential values of −31 ± 0.1 mV and a single melting peak of 55.85°C. Immunohistochemical methods revealed that TQNLCs inhibited the formation of ethanol-induced ulcers through the modulation of heat shock protein-70 (Hsp70). Acute hepatotoxic effects of the TQNLCs were not observed in rats or normal human liver cells (WRL-68). After validation, PK studies in rabbits showed that the PK properties of TQ were improved and indicated that the drug behaves linearly. The Tmax, Cmax, and elimination half-life of TQ were found to be 3.96 ± 0.19 hours, 4811.33 ± 55.52 ng/mL, and 4.4933 ± 0.015 hours, respectively, indicating that TQ is suitable for extravascular administration. Conclusion NLCs could be a promising vehicle for the oral delivery of TQ and improve its gastroprotective properties.

[1]  A. Rasedee,et al.  Characterization and Cytotoxicity of Nanostructured Lipid Carriers Formulated With Olive Oil, Hydrogenated Palm Oil, and Polysorbate 80 , 2013, IEEE Transactions on NanoBioscience.

[2]  F. Ahmad,et al.  Nanocarrier based formulation of Thymoquinone improves oral delivery: stability assessment, in vitro and in vivo studies. , 2013, Colloids and surfaces. B, Biointerfaces.

[3]  G. Mustafa,et al.  Development and evaluation of thymoquinone-encapsulated chitosan nanoparticles for nose-to-brain targeting: a pharmacoscintigraphic study , 2012, International journal of nanomedicine.

[4]  C. Lehr,et al.  Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[5]  T. Cardoso,et al.  Thymoquinone β-Cyclodextrin Nanoparticles System: A Preliminary Study , 2012 .

[6]  F. Tanfani,et al.  Characterization of thymoquinone binding to human α₁-acid glycoprotein. , 2012, Journal of pharmaceutical sciences.

[7]  G. Sethi,et al.  Thymoquinone: potential cure for inflammatory disorders and cancer. , 2012, Biochemical pharmacology.

[8]  S. M. Faisal,et al.  Acrylated vegetable oil nanoparticle as a carrier and controlled release of the anticancer drug-thymoquinone , 2012, 2012 International Conference on Enabling Science and Nanotechnology.

[9]  Noha M. Shawky,et al.  Comparative evaluation of anti-inflammatory properties of thymoquinone and curcumin using an asthmatic murine model. , 2011, International immunopharmacology.

[10]  M. E. Morales,et al.  Lipid-based drug delivery systems for cancer treatment. , 2011, Current drug targets.

[11]  D. Vohora,et al.  Stability-indicating ultra-performance liquid chromatography method for the estimation of thymoquinone and its application in biopharmaceutical studies. , 2011, Biomedical chromatography : BMC.

[12]  K. M. Khawar,et al.  Preliminary report on hepatic and cardiovascular risk assessment of automobile mechanics in Nigeria , 2011 .

[13]  M. Werner,et al.  Antiulcerogenic activity of hydroalcoholic extract of Achillea millefolium L.: involvement of the antioxidant system. , 2010, Journal of ethnopharmacology.

[14]  B. Aggarwal,et al.  Thymoquinone poly (lactide-co-glycolide) nanoparticles exhibit enhanced anti-proliferative, anti-inflammatory, and chemosensitization potential. , 2010, Biochemical pharmacology.

[15]  R. Thiruganesh,et al.  Solid lipid nanoparticle and nanoparticle lipid carrier for controlled drug delivery – a review of state of art and recent advances , 2010 .

[16]  A. Pichette,et al.  Bioactivities of black cumin essential oil and its main terpenes from Tunisia , 2010 .

[17]  A. Abdul,et al.  Validated high performance liquid chromatographic (HPLC) method for analysis of zerumbone in plasma , 2010 .

[18]  N. Ismail,et al.  Antioxidant activity and phenolic content of phenolic rich fractions obtained from black cumin (Nigella sativa) seedcake. , 2009 .

[19]  V. Kadam,et al.  Solid lipid nanoparticles and nanostructured lipid carriers--innovative generations of solid lipid carriers. , 2008, Current drug delivery.

[20]  Jia-You Fang,et al.  Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion , 2008, Acta Pharmacologica Sinica.

[21]  Nelson Durán,et al.  New aspects of nanopharmaceutical delivery systems. , 2008, Journal of nanoscience and nanotechnology.

[22]  D. Hauss Oral lipid-based formulations. , 2007, Advanced drug delivery reviews.

[23]  X. Wu,et al.  Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. , 2007, Advanced drug delivery reviews.

[24]  W. Vilegas,et al.  Effect of Mouriri pusa extracts on experimentally induced gastric lesions in rodents: role of endogenous sulfhydryls compounds and nitric oxide in gastroprotection. , 2006, Journal of ethnopharmacology.

[25]  S. Guterres,et al.  Preparation, characterization, and in vivo anti-ulcer evaluation of pantoprazole-loaded microparticles. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[26]  M. Salem Immunomodulatory and therapeutic properties of the Nigella sativa L. seed. , 2005, International immunopharmacology.

[27]  M. Kanter,et al.  Gastroprotective activity of Nigella sativa L oil and its constituent, thymoquinone against acute alcohol-induced gastric mucosal injury in rats. , 2005, World journal of gastroenterology.

[28]  B. Ali,et al.  Pharmacological and toxicological properties of Nigella sativa , 2003, Phytotherapy research : PTR.

[29]  S. Saleh,et al.  Gastroprotective activity of Nigella sativa oil and its constituent, thymoquinone, against gastric mucosal injury induced by ischaemia/reperfusion in rats. , 2003, Journal of ethnopharmacology.

[30]  R. Müller,et al.  Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. , 2002, Advanced drug delivery reviews.

[31]  B. Nyassé,et al.  Gastric cytoprotective anti-ulcer effects of the leaf methanol extract of Ocimum suave (Lamiaceae) in rats. , 2002, Journal of ethnopharmacology.

[32]  F. Bucar,et al.  Antioxidant activity of Nigella sativa essential oil , 2000, Phytotherapy research : PTR.

[33]  R. Müller,et al.  Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[34]  M. Lacaille‐Dubois,et al.  [Diuretic and hypotensive effects of Nigella sativa in the spontaneously hypertensive rat]. , 2000, Therapie.

[35]  Y. Raji,et al.  Methyl angolensate: the antiulcer agent of the stem bark of Entandrophragma angolense. , 1995, Planta medica.

[36]  J. Hunter,et al.  Epidermal growth factor stimulates synthesis and secretion of mucus glycoproteins in human gastric mucosa. , 1990, Clinical science.

[37]  J. Crow Electron Microscopy in Human Medicine , 1981 .

[38]  N. Seetapan,et al.  Rheological and morphological characterizations on physical stability of gamma-oryzanol-loaded solid lipid nanoparticles (SLNs). , 2010, Micron.

[39]  Peeyush Kumar,et al.  A REVIEW ON NOVEL LIPID BASED NANOCARRIERS , 2010 .

[40]  Robert Blumenthal,et al.  Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. , 2009, Critical reviews in therapeutic drug carrier systems.

[41]  N. K. Jain,et al.  Clarithromycin- and omeprazole-containing gliadin nanoparticles for the treatment of Helicobacter pylori. , 2008, Journal of drug targeting.

[42]  O. Behmer,et al.  Manual de técnicas para histologia: normal e patológica , 2003 .

[43]  J. Wallace,et al.  The roles of ethanol and of acid in the production of gastric mucosal erosions in rats , 1981, Virchows Archiv. B, Cell pathology including molecular pathology.